StockData
HOWLNasdaqPharmaceutical PreparationsFiscal year ends December 31

Werewolf Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.04+0.06 (+6.12%)

Close on Oct 19, 2026

Market cap
$50.54M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 31, 2026Before market open$21.00M$0.08–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026During market hours–$-0.28–
Q4 FY2025
Ended Dec 31, 2025
Mar 27, 2026Before market open–$-0.20–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025Before market open–$-0.36–
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$-0.40–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 11, 2025Before market open–$-0.46–
Q3 FY2024
Ended Sep 30, 2024
Nov 7, 2024Before market open–$-0.38–
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024Before market open$1.10M$-0.43–
Q1 FY2024
Ended Mar 31, 2024
May 3, 2024Before market open$700.00K$-0.39–
Q4 FY2023
Ended Dec 31, 2023
Mar 7, 2024Before market open$1.50M$-0.33–

Press releases

Announcements Werewolf Therapeutics filed with the SEC